Company Overview
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Why Investors Should Care
Net profit has compounded at 15.1% per year over the last five years.
Carries low leverage with a debt-to-equity ratio of 0.37.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR 15.1%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | 15.14% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -61.48% |
| 6 Months: | -53.04% |
| 3 Months: | +7.22% |
| 1 Month: | +12.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)47.64 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 15.1% over 5 years.
CONS
- Trading 67.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALDX Aldeyra Therapeutics, Inc. R2K | 1.93 | -4.29 | $116.42M | 0.00% | -72.18% | -51.76% | - | 15.14% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.43M | 10.17M | 8.00M | 6.67M | 3.55M |
| Operating Income | -985.69K | -1.17M | -1.24M | -1.65M | -1.97M | -2.11M | -2.20M | -3.34M | -4.97M | -4.30M | -4.78M | -5.10M | -5.33M | -5.02M | -8.49M | -9.17M | -10.95M | -17.43M | -13.73M | -19.02M | -9.64M | -7.11M | -8.39M | -10.83M | -14.54M | -15.44M | -16.48M | -17.71M | -14.78M | -16.80M | -10.34M | -9.55M | -9.39M | -18.01M | - | -10.43M | -10.17M | -8.00M | -6.67M | -3.55M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.39M | -9.23M | -7.15M | -5.92M | -2.92M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 483.53K | 470.62K | 475.90K | 475.26K | 468.68K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.93M | -9.77M | -7.69M | -6.46M | -3.45M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.57M | 9.31M | 401.77K | -1.14M | -2.01M | -2.14M | -2.23M | -3.37M | -4.97M | -4.30M | -4.78M | -5.09M | -5.31M | -4.99M | -8.40M | -9.05M | -10.81M | -15.62M | -13.33M | -18.72M | -9.87M | -7.52M | -8.87M | -11.29M | -14.94M | -15.79M | -16.79M | -17.78M | -14.55M | -15.62M | -8.99M | -8.19M | -8.08M | -16.85M | - | -9.93M | -9.77M | -7.69M | -6.46M | -3.45M |
| Diluted EPS | -5.47 | -9.81 | -4.04 | -1.56 | -0.36 | -0.32 | -0.27 | -0.35 | -0.51 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.28 | -0.27 | -0.29 | -0.30 | -0.25 | -0.27 | -0.15 | -0.14 | -0.14 | -0.28 | -0.25 | -0.17 | -0.16 | -0.13 | - | -0.06 |
| R&D Expense | 325.05K | 666.04K | 444.28K | 663.91K | 1.20M | 1.14M | 1.25M | 2.08M | 3.51M | 2.83M | 3.38M | 3.37M | 3.85M | 3.54M | 6.60M | 6.79M | 7.88M | 7.85M | 10.66M | 16.22M | 6.63M | 4.89M | 6.13M | 7.73M | 11.47M | 12.89M | 12.23M | 14.57M | 11.54M | 11.24M | 6.96M | 6.96M | 6.18M | 14.97M | 12.44M | 7.42M | 8.51M | 5.43M | - | 2.41M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 62.68M | 42.79M | 60.12M | 35.27M |
| Operating Income | -3.68M | -7.27M | -11.99M | -18.70M | -22.49M | -39.70M | -63.07M | -36.42M | - | -62.68M | -42.79M | -60.12M | -35.27M |
| EBITDA | - | - | - | - | - | - | - | - | - | -60.07M | -35.21M | -53.68M | -31.69M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 1.69M | 2.07M | 1.93M | 1.91M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -62.02M | -37.54M | -55.85M | -33.85M |
| Tax Provision | - | - | - | - | - | - | - | - | 0 | - | - | - | - |
| Net Income | 13.06M | -5.19M | -12.09M | -18.70M | -22.34M | -38.89M | -60.83M | -37.55M | - | -62.02M | -37.54M | -55.85M | -33.85M |
| Diluted EPS | -17.61 | -3.09 | -1.40 | - | - | - | - | - | - | -1.06 | -0.64 | -0.94 | -0.56 |
| R&D Expense | 1.54M | 3.71M | 7.57M | 13.18M | 16.30M | 29.82M | 44.35M | 24.68M | 44.94M | 47.31M | 29.46M | 48.22M | 25.66M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 3.74M | 8.79M | 28.20M | - | 25.19M | 44.17M | 95.09M | 75.52M | 83.35M | - | 181.29M | 148.33M | 104.61M | 72.06M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 181.02M | 147.81M | 104.07M | 71.78M |
| Cash & Equivalents | 1.22M | 3.26M | 8.53M | 14.65M | 14.65M | 12.02M | 20.02M | 47.36M | 44.43M | 77.86M | - | 144.42M | 142.82M | 54.53M | 70.04M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | 28.77K | 3.24M | 0 | - | - |
| Total Liabilities | - | 5.65M | 2.50M | 3.33M | - | 3.54M | 4.57M | 8.47M | 27.44M | 23.84M | - | 30.28M | 28.53M | 33.60M | 27.81M |
| Current Liabilities | - | 605.01K | 1.33M | 2.12M | - | 2.30M | 3.35M | 8.47M | 12.91M | 12.41M | - | 15.36M | 22.26M | 18.60M | 27.81M |
| Long Term Debt | - | 1.13M | 1.18M | 1.21M | - | 1.24M | 1.22M | - | 14.53M | 11.43M | 15.50M | 14.92M | - | 15.00M | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 16.08M | 15.66M | 15.30M | 15.53M |
| Total Equity | -54.38M | -40.22M | 6.28M | 24.88M | 24.88M | 21.65M | 39.60M | 86.62M | 48.08M | 59.51M | - | 151.01M | 119.80M | 71.00M | 44.25M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 58.56M | 59.20M | 59.65M | 60.16M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -19.22M | -29.86M | -44.98M | -37.49M | - | -56.64M | -30.33M | -43.21M | -33.35M |
| Investing Cash Flow | - | - | - | -10.20M | -23.34M | 18.48M | 29.02M | - | -29.95M | 30.00M | -44.92M | 47.74M |
| Financing Cash Flow | - | - | - | 37.43M | 80.53M | 23.58M | 41.90M | - | 1.22M | -1.27M | -171.42K | 1.12M |
| Capital Expenditure | -14.06K | -86.12K | -11.81K | -24.76K | -262.97K | -9.53K | - | -7.81K | -16.32K | - | - | - |
| Free Cash Flow | - | - | - | -19.25M | -30.12M | -44.99M | - | - | -56.65M | -30.33M | -43.21M | -33.35M |
| Net Change in Cash | - | - | - | - | - | - | - | - | -85.37M | -1.60M | -88.30M | 15.51M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | -32.5% | -82.5% | -48.6% | -86.4% | -56.4% | -44.9% | -126.5% | -63.1% | - | -41.1% | -31.3% | -78.7% | -76.5% |
| ROCE % | -117.1% | -97.5% | -46.0% | -81.7% | -55.1% | -45.8% | -100.7% | -51.3% | - | -37.8% | -33.9% | -69.9% | -79.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Knoll Capital Management, LLC | 9.08% | 5.48M | $12.59M |
| 2 | Blackrock Inc. | 6.24% | 3.76M | $8.65M |
| 3 | AQR Capital Management, LLC | 4.69% | 2.83M | $6.50M |
| 4 | Vanguard Capital Management LLC | 3.92% | 2.36M | $5.43M |
| 5 | Kingdon Capital Management LLC | 3.57% | 2.15M | $4.95M |
| 6 | 683 Capital Management LLC | 2.49% | 1.50M | $3.45M |
| 7 | Shaw D.E. & Co., Inc. | 2.33% | 1.40M | $3.23M |
| 8 | Geode Capital Management, LLC | 2.07% | 1.25M | $2.88M |
| 9 | State Street Corporation | 1.86% | 1.12M | $2.59M |
| 10 | Millennium Management Llc | 1.65% | 995.24K | $2.29M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALDX
Levicept Appoints Darlene Deptula-Hicks as CFO
Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for OsteoarthritisSANDWICH, United Kingdom, July 07, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focus…
CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock
Investors who take an interest in Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) should definitely note that the CEO...
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
LEXINGTON, Mass., June 10, 2026--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appoint…
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tie…
3 Promising Penny Stocks With Market Caps Reaching $300M
The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 17% annually. Investing in penny stocks—once a buzzword but now more of a niche—can still open doors to growth opportunities…
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
LEXINGTON, Mass., June 02, 2026--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C…
ALDX — Frequently Asked Questions
What is the current share price of Aldeyra Therapeutics, Inc. (ALDX)?
As of 2026-07-14 21:23 PDT, Aldeyra Therapeutics, Inc. (ALDX) trades at $1.93 on NasdaqCM. Its 52-week range is $1.24 to $5.89.
What is the market capitalisation of ALDX?
Aldeyra Therapeutics, Inc. (ALDX) has a market capitalisation of $116.42M on NasdaqCM.
What is the P/E ratio of ALDX?
ALDX trades at a trailing price-to-earnings (P/E) ratio of -4.29. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.52.
What is the return on equity (ROE) of ALDX?
ALDX has a return on equity (ROE) of -51.76%. Its return on capital employed (ROCE) is -72.18%.
Is ALDX a good stock to buy?
This page provides a data-driven analysis of Aldeyra Therapeutics, Inc. (ALDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.